Tengion Announces Promotion of A. Brian Davis to Chief Financial Officer and Senior Vice President, Finance

 Tengion Announces Promotion of A. Brian Davis to Chief Financial Officer and
                        Senior Vice President, Finance

PR Newswire

WINSTON-SALEM, N.C., Aug. 7, 2013

WINSTON-SALEM, N.C., Aug. 7, 2013 /PRNewswire/ --Tengion, Inc. (OTCQB: TNGN),
a leader in regenerative medicine, today announced the promotion of A. Brian
Davis to Chief Financial Officer and Senior Vice President, Finance. Mr. Davis
has served as Chief Financial Officer of Tengion since joining the Company in
2010 and recently helped facilitate the Company in raising $33.6M to fund
research and development activities for its two lead clinical programs, the
Neo-Kidney Augment™ and the Neo-Urinary Conduit™.

"Brian has demonstrated exceptional execution in leading Tengion's financial
efforts and has been instrumental in several transformative events for the
Company, including the recent strategic investment from Celgene and
simultaneous financing," commented John L. Miclot, President and Chief
Executive Officer of Tengion. "We look forward to continuing the development
of our Organ Regeneration Platform™ under Brian's financial leadership to
drive further value and growth for Tengion."

Prior to joining Tengion, Mr. Davis served 15 years at Neose Technologies,
Inc., a biopharmaceutical company using enzymatic technologies to develop
improved protein therapeutics, where he advanced from Controller to Senior
Vice President, Finance and CFO. He holds a B.S. in Accounting from Trenton
State College and an M.B.A. from the Wharton School of the University of
Pennsylvania. He is a Certified Public Accountant.

"Brian is an integral part of our team, and this promotion is well-deserved,"
said David Scheer, Chairman of the Tengion Board of Directors. "We
congratulate Brian and thank him for his dedicated and tireless commitment to
the company."

About Tengion

Tengion, a clinical-stage regenerative medicine company, is focused on
developing its Organ Regeneration Platform™ to harness the intrinsic
regenerative pathways of the body to regenerate a range of native-like organs
and tissues with the goal of delaying or eliminating the need for chronic
disease therapies, organ transplantation, and the administration of
anti-rejection medications. The Company commenced a Phase 1 clinical trial in
May 2013 for its Neo-Kidney Augment™, which is designed to prevent or delay
dialysis or kidney transplantation by increasing renal function in patients
with advanced chronic kidney disease. The Company is conducting this initial
clinical trial in Sweden and is actively enrolling patients with chronic
kidney disease and anticipates commencement of an initial clinical trial in
the United States during the fourth quarter of 2013. An initial clinical trial
is ongoing for the Company's Neo-Urinary Conduit™, an autologous implant that
is intended to catalyze regeneration of native-like urinary tissue for bladder
cancer patients requiring a urinary diversion following bladder removal.

SOURCE Tengion, Inc.

Website: http://www.tengion.com
Contact: Brian Davis, brian.davis@tengion.com, 336.201.0155
Press spacebar to pause and continue. Press esc to stop.